In the mice models of the four tumors, consistent with the decline of ACLY, evident lower levels of FASN and HMGCR expression were revealed by IHC staining after the anti-tumor treatment of miR-22 (Figures 6H and S5). The gene discussed is HMGCR; the disease is neoplasm.